-
Product Insights
NewNet Present Value Model: Purple Biotech Ltd’s CM-24
Empower your strategies with our Net Present Value Model: Purple Biotech Ltd's CM-24 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-101 in Liver Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CM-101 in Liver Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Liver Fibrosis Drug Details: CM-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-101 in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CM-101 in Primary Sclerosing Cholangitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Primary Sclerosing Cholangitis Drug Details: CM-101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy Drug Details: BBP-265...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-24 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CM-24 in Pancreatic Ductal Adenocarcinoma Drug Details: CM-24 is under development for pancreatic cancer, melanoma, ovarian cancer,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALXN-2220 in Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALXN-2220 in Amyloid Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALXN-2220 in Amyloid Cardiomyopathy Drug Details: NI-301 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NTLA-2001 in Familial Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NTLA-2001 in Familial Amyloid Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NTLA-2001 in Familial Amyloid Cardiomyopathy Drug Details: NTLA-2001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zegocractin in Pancreatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zegocractin in Pancreatitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zegocractin in Pancreatitis Drug Details: Zegocractin (CM-4620) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALXN-2220 in Familial Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALXN-2220 in Familial Amyloid Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALXN-2220 in Familial Amyloid Cardiomyopathy Drug Details: NI-301 is under...
-
Product Insights
NewEndonovo Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Endonovo Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices. The company’s products include Electroceutical Therapy a FDA-Cleared for the palliative treatment of pain and post-surgical edema and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Its Electroceutical Therapy has CMS National Coverage for...